The potential blockbuster drug was approved by the agency more than a month before its scheduled decision date. A potential blockbuster cancer drug developed by Genentech Inc. and parent company ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Nykode Therapeutics (VACBF) announced last night that it has received notification from Genentech, a member of the Roche (RHHBY), of its ...

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its PDUFA date, the agency approved the firm’s first-line breast cancer treatment ...

Genentech, a member of the Roche ... types of metastatic bladder or urinary tract cancer. Following a consultation with the US Food and Drug Administration (FDA), and in accordance with the ...

Finally, Genentech’s alliance with Skyhawk covers the development and commercialisation of small-molecule drugs that modulate RNA splicing, with a particular focus on cancer and ...

Highlighted by Genentech's recent US regulatory ... utilize disulphide bonds that are cleavable inside cancer cells and, once the cytotoxic drug is released, will allow for the possibility of ...

Roche Group unit Genentech said that the Food and Drug Administration approved Itovebi for treating certain breast cancer. The approval is for Itovebi in combination with palbociclib and ...

Genentech, a member of the Roche ... portfolio and clinical director of the early drug development service at Memorial Sloan Kettering Cancer Center, and one of the principal investigators of ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration approved ... locally advanced or metastatic breast cancer, as detected by an FDA ...

marking an important step in our ambition to continue bringing innovative medicines to more people with breast cancer – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced ...